Disc Medicine, Inc. (IRON) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $66.42: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum.
Disc Medicine is a clinical-stage biopharma focused on hematologic diseases, with lead programs bitopertin (EPP/XLP, Phase 3 APOLLO trial underway), DISC-0974 (anemia of MF/IBD), and DISC-3405 (polycythemia vera, SCD). The company received an FDA complete response letter for the... Read more
Sell if holding. Engine safety override at $66.42: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-27Item 2.05MEDIUMBoard approved restructuring plan February 26, 2026, reducing workforce ~20% primarily in commercial functions, following FDA CRL for bitopertin NDA. ~$2.0M charges expected (primarily severance) Q1 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $66.42: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 4.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $61.73. Score 4.6/10, moderate confidence.
Take-profit target: $87.15 (+31.3% upside). Prior stop was $61.73. Stop-loss: $61.73.
Quality below floor (1.4 < 4.0).
Disc Medicine, Inc. trades at a P/E of N/A (forward -8.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover IRON with a consensus score of 4.3/5. Average price target: $100.
What does Disc Medicine, Inc. do?Disc Medicine is a clinical-stage biopharma focused on hematologic diseases, with lead programs bitopertin (EPP/XLP,...
Disc Medicine is a clinical-stage biopharma focused on hematologic diseases, with lead programs bitopertin (EPP/XLP, Phase 3 APOLLO trial underway), DISC-0974 (anemia of MF/IBD), and DISC-3405 (polycythemia vera, SCD). The company received an FDA complete response letter for the bitopertin NDA in February 2026 and has no approved products. Accumulated deficit was $510.2M as of December 31, 2025.